Navigation Links
Accuray Incorporated's CEO to Speak at UBS Global Life Sciences Conference
Date:9/16/2010

SUNNYVALE, Calif., Sept. 16 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its president and chief executive officer, Euan S. Thomson, Ph.D., is scheduled to present at the UBS Global Life Sciences Conference in New York City on Tuesday, September 21, 2010 at 2:00 p.m. ET/11:00 a.m. PT.

A live webcast of the presentation will be available online from the investor relations page of the Company's Web site at http://www.accuray.com.  The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately 30 days.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
2. Accurays CyberKnife® G4 System Receives Shonin Approval
3. Accuray Incorporateds CEO to Speak at BMO Capital Markets Tenth Annual Focus on Healthcare Conference
4. Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010
5. Accuray Appoints Peter Fine to Board of Directors
6. Accuray Installs 200th CyberKnife Robotic Radiosurgery System
7. Accuray Incorporated to Present at Citi Global Health Care Conference
8. Accuray Hires General Manager for the EIMEA Region
9. Accuray Announces Results for Second Quarter Fiscal 2010
10. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
11. Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... clearance for and commercializing its CE Marked APPY ... identifying children, adolescent, and young adult patients in the ... today announced it will present at three upcoming investor ... Global Investment Conference being held in New ...
(Date:8/28/2014)... MEETING, Pa. , Aug. 28, 2014 /PRNewswire-USNewswire/ ... community, patients, and media, both for the promise ... patient safety. The quick deployment of surgical robots ... technology are prompting facilities to evaluate their robotic ... the entire surgical team.    ECRI ...
(Date:8/28/2014)... 28, 2014  Critical Process Filtration, Inc. of ... announces the expansion of their Technical Services and ... now offers customers and potential customers services ranging ... failure analyses (even for competitor filters) and contaminant ... services of system benchmarking and cost/performance optimization. ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:8/29/2014)... 29, 2014 "I have had many hospital ... well as many other surgeries in my lifetime, as I ... "During my stays, I was unable to move freely in ... Two nurses freely had to physically rotate me every 30 ... of me and pulled the sheets. This was jarring and ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Scientists from ... idea that progression-free survival correlates with overall survival of ... the new research. Click here to read it ... The Netherlands studied the cases of 523 mesothelioma ... studies. , “PFSR-18 [progression-free survival at 18 weeks ...
(Date:8/29/2014)... Diego, CA (PRWEB) August 29, 2014 A ... sun protection. The dangers of overexposure to the sun are ... consistently as they should. Sun damage often doesn’t manifest itself ... a recent project by artist Thomas Leveritt showed, even if ... Leveritt used a special ultraviolet camera in order to show ...
(Date:8/29/2014)... 29, 2014 According to these recent findings, ... Herpes and HPV cases in the last few years. Medical ... nature of these infections and the symptoms that make it ... STD. While some people aren't aware of the exact symptoms ... , The steady increase in the number of cases over ...
(Date:8/29/2014)... Penn. (PRWEB) August 29, 2014 According ... Cancer Intelligence Network (NCIN) conference held in Birmingham, England ... patients will have their disease recur”. This only goes ... for those who are struggling to fight its grueling ... story of one woman’s journey through breast cancer is ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client Develops Equipment for Surgical and Bedridden Patients (HCD-279) 2Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Artist Uses Ultraviolet Camera to Reveal Hidden Sun Damage 2Health News:Artist Uses Ultraviolet Camera to Reveal Hidden Sun Damage 3Health News:It was reported that the Number on PositiveSingles.dating increased about 20% in 2014 2Health News:Lisa Grimaldi Shares Her Fashionable Journey through Breast Cancer 2
... 1 Arete Therapeutics Inc. today,announced the initiation ... lead compound,AR9281, for the treatment of hypertension. AR9281 ... (s-EH), a novel target,for the treatment of hypertension. ... volunteers and will evaluate the safety, tolerability,pharmacokinetics and ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... BASINGSTOKE, England and PHILADELPHIA, November 1, Shire plc (LSE: SHP, ... for the third,quarter 2007. Q3 2007 Financial Highlights ... Total revenues up 35% to $608.7 million; - Net ... and - 2007 revenue growth now expected to be ...
... Innovative Approach to Preventing Kidney Damage during ... ... (Amex: PLC ), a,company focused on innovative cardiac and vascular ... Renal Week, the American Society of Nephrology,s 40th,Annual Meeting and Scientific ...
... of the cells might lead to treatments, researchers say , THURSDAY, ... found stem cells within the intervertebral discs of the human spine. ... stem cells to help repair degenerating discs in order to treat ... the Nov. 1 issue of the journal Spine . , ...
Cached Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31
... speed and accuracy allow clinical staff ... timely manner - something everyone in ... In fact, the Rapidlab 1200 delivers ... one minute. Its maintenance-free, cartridge-based system ...
... Fibertom is a 60 watt diode continuous wave ... of Diode Power Bar technology and 940 nm ... laser treatment for varicose veins and a variety ... includes unique safety features including the LPS, Light ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
... disc test for detecting and grading ... minutes for quantitative estimation of saturation ... sensitive to and specific for differences ... Combined with Ishiharas pseudo-isochromatic plates, discriminates ...
Medicine Products: